Benitec Biopharma (BNTC) Equity Average (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Equity Average for 7 consecutive years, with -$109.7 million as the latest value for Q1 2025.
- Quarterly Equity Average fell 913.39% to -$109.7 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$109.7 million through Mar 2025, down 913.39% year-over-year, with the annual reading at $23.7 million for FY2024, 1438.59% up from the prior year.
- Equity Average hit -$109.7 million in Q1 2025 for Benitec Biopharma, down from -$97.7 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $29.4 million in Q2 2024 to a low of -$109.7 million in Q1 2025.
- Historically, Equity Average has averaged -$6.2 million across 5 years, with a median of $11.3 million in 2023.
- Biggest five-year swings in Equity Average: surged 1095.28% in 2024 and later plummeted 913.39% in 2025.
- Year by year, Equity Average stood at $13.2 million in 2021, then dropped by 10.28% to $11.8 million in 2022, then surged by 60.03% to $18.9 million in 2023, then tumbled by 617.01% to -$97.7 million in 2024, then dropped by 12.31% to -$109.7 million in 2025.
- Business Quant data shows Equity Average for BNTC at -$109.7 million in Q1 2025, -$97.7 million in Q4 2024, and -$74.0 million in Q3 2024.